Skip to main content
← All articles

6 Quick Checks for Algorithmic Bias in Australian Healthcare

Decorative healthcare algorithm bias title card

Algorithmic bias in healthcare happens when a clinical AI system performs unevenly across patient groups, often hidden behind strong overall accuracy. The single most important action for practitioners and policy teams is to disaggregate performance metrics by subgroup and keep a clinician making the final call, rather than trusting an aggregate score. NSW ACI guidance is explicit that clinicians remain responsible for safe and equitable use of AI tools.

TL;DR:

  • Disaggregated performance metrics by subgroup are essential because overall accuracy can mask significant biases against specific patient groups.
  • Bias can enter at multiple points in the AI lifecycle, from data collection and labeling to model design, evaluation, deployment, and feedback, requiring controls at each stage.
  • Fairness reporting should include subgroup-level sensitivity, specificity, calibration, and detailed documentation to detect and manage underperformance effectively.
  • Ongoing post-market surveillance, frequent subgroup audits, and configurable fairness thresholds are critical to catching bias that develops over time or in real-world settings.
  • Practitioners remain responsible for clinical decisions, and vendors should provide detailed subgroup validation data before procurement to prevent reliance on incomplete performance information.
Meddle
Find Healthcare That Fits Your Needs
Meddle uses AI-powered matching to connect you with practitioners based on your individual symptoms and preferences.
Find your practitioner

Table of Contents

What algorithmic bias is and why it matters in clinical practice

Algorithmic bias is systematic underperformance or unfair treatment produced by an AI system for particular groups of patients, even when the system reports excellent accuracy overall. A model can score 95% accuracy across a full population while performing far worse for a specific age band, ethnic group or disease presentation. That gap is invisible unless someone looks for it, which is why aggregate metrics are a weak foundation for trusting clinical AI.

It helps to separate bias into where it comes from. Data bias occurs when training data under-represents a cohort, for example a skin lesion classifier trained mostly on lighter skin tones. Label bias occurs when the ground truth itself reflects historical inequity, such as under-diagnosis of pain in some populations shaping what the model learns to call “normal”. Sample bias reflects who was available to be measured in the first place, often skewed towards patients who already had better access to care. Measurement bias arises when a proxy variable, like healthcare spending as a stand-in for health need, systematically understates need in groups with historically lower access. Automation bias is the human factor: clinicians trusting an algorithmic output more than their own judgement simply because it came from a system, which compounds every other category above.

These categories are not academic. A widely discussed United States case found that an algorithm used to allocate extra care resources ranked Black patients as lower risk than white patients with the same level of underlying illness, because it used prior healthcare spending as a proxy for health need rather than actual need. Patients with less historical access to care looked “healthier” to the algorithm purely because they had spent less on care. The fix was not to scrap the tool but to change the proxy variable and retest by subgroup.

Clinical imaging offers a parallel lesson. Dermatology and radiology models trained predominantly on one skin tone or one scanner type can lose substantial sensitivity when applied to under-represented groups, even while the published accuracy figure for the whole validation set looks strong. The AHRC technical paper on algorithmic bias frames this as a core reason why bias mitigation needs to be treated as a lifecycle discipline, not a one-off check before launch.

The practical takeaway for clinical teams is straightforward: a single headline accuracy number tells you almost nothing about whether a tool is safe for every patient in front of you. You need the breakdown, not the average.

Aggregate accuracy hiding subgroup performance gaps

Where bias arises in the AI lifecycle

Bias rarely enters at one point. It accumulates across the build and deployment pipeline, and each stage needs its own controls.

Data collection is the first and most consequential stage. If a training dataset draws heavily from one hospital network, one age bracket or one geographic region, the model will reflect that population’s patterns and may degrade sharply outside it. Representativeness gaps are often invisible in a model card that only reports where data came from in aggregate, not how thin coverage is for smaller cohorts.

Labelling and annotation introduce a second layer. Ground-truth labels are usually produced by clinicians working from existing records, and those records already carry the imprint of historical access gaps, diagnostic delay or clinician bias in prior encounters. A model trained on biased labels will learn to reproduce that bias with mathematical confidence.

Model design choices then decide how those data problems play out in practice. Selecting a proxy feature such as cost of care, length of stay or number of prior visits as a stand-in for severity can bake inequity directly into the model’s logic, as the allocation algorithm case above shows. Feature selection, loss function choices and which error type the team optimises against (false positives versus false negatives) all shift who bears the cost of the model’s mistakes.

Evaluation is where many of these problems should be caught but often are not, because teams report one accuracy figure for the whole test set rather than a breakdown by age, sex, ethnicity, language or comorbidity.

Deployment and feedback loops close the circle. Once live, a model’s outputs can influence future data: if a triage tool deprioritises a cohort, that cohort generates fewer downstream records of severe outcomes, which can make the model look more “correct” over time even as it causes harm. The AI technical standard, Statement 6 requires bias to be managed across this entire lifecycle, not patched once at validation.

Five-stage AI bias lifecycle diagram

How to measure harm: fairness metrics and the case for disaggregation

You cannot manage what you have not measured by subgroup. A model’s overall sensitivity and specificity say nothing about whether it works equally well for the patients you see most and least often, and Australian technical guidance now expects disaggregated reporting as standard practice.

Statistical parity checks whether a positive prediction rate is similar across groups, useful for screening tools where unequal flagging rates signal a problem worth investigating. Equal opportunity focuses on whether true positive rates (the model’s ability to correctly flag patients who truly have the condition) are consistent across subgroups, which matters more in diagnostic contexts than raw parity. Calibration asks whether a predicted risk score of, say, 70% actually corresponds to a 70% real-world event rate within each subgroup, not just overall. Disparate impact measures whether one group is disproportionately denied a beneficial outcome, such as referral to a specialist. Cohort-level sensitivity and specificity (not just overall) is the minimum breakdown every clinical validation report should include.

Choosing which metric to prioritise depends on the clinical use case:

  • Screening and triage tools should prioritise equal opportunity and sensitivity by subgroup, since a missed case carries the highest cost.
  • Risk-scoring tools used for resource allocation should prioritise calibration and disparate impact, since miscalibrated risk scores directly shape who gets care.
  • Diagnostic classifiers need sensitivity and specificity reported separately for every clinically relevant subgroup, not a single pooled figure.
  • Administrative and scheduling algorithms should be checked for statistical parity in who gets flagged, delayed or deprioritised.

Disaggregated performance metrics, stakeholder engagement and ongoing monitoring are required by Australia’s AI technical standard to detect underperformance that a single aggregate accuracy figure would hide. That requirement should shape what a fairness report actually contains.

A minimal fairness report for any clinical AI tool should include: the subgroups tested (at minimum age, sex, and where data permits, ethnicity and language), sensitivity and specificity for each subgroup, calibration curves by subgroup, the size of each subgroup in the validation set (so readers can judge statistical confidence), and a plain-language statement of known limitations. The AHRC technical paper recommends documenting these decisions and the reasoning behind them as part of an ongoing audit trail, not a one-time compliance exercise.

Practical detection and audit methods for clinical AI

Detecting bias is a repeatable process, not a single pre-launch test. A working audit runs in stages, each building on the last.

  1. Check data provenance and coverage first. Ask where the training and validation data came from, how many patients represent each clinically relevant subgroup, and whether any group is thin enough that reported metrics for it are statistically unreliable.
  2. Build disaggregated test suites. Split the validation set by age, sex, ethnicity, language and relevant comorbidities, then report sensitivity, specificity and calibration separately for each.
  3. Run counterfactual tests. Change a single demographic attribute in an otherwise identical case and check whether the model’s output shifts in ways that are not clinically justified.
  4. Stress test at the edges. Evaluate performance for rare presentations, atypical symptom combinations and cohorts with small sample sizes, since these are where bias hides most reliably.
  5. Automate recurring scans. Schedule subgroup performance checks on a fixed cadence rather than only at initial validation, since model drift can introduce new bias as real-world data shifts.
  6. Link audit findings to incident reporting. Route any flagged disparity into the same escalation pathway used for clinical safety incidents, so a fairness finding gets the same follow-through as any other patient safety concern.
  7. Interrogate suppliers before procurement. Request subgroup-level validation results, not just an aggregate accuracy figure, along with a clear description of training data composition and a commitment to post-market monitoring.

The NSW ACI’s 2025 guidance makes post-market surveillance a named requirement precisely because models can drift as populations and clinical practice change after deployment. An audit finished at go-live tells you nothing about year two.

Comparing audit depth against typical procurement practice is instructive. Many health services still accept a vendor’s single aggregate accuracy claim at face value, treat a glossy validation study as sufficient evidence, and never revisit performance once the tool is embedded in workflow. A disaggregated audit, by contrast, demands subgroup breakdowns before purchase, scheduled re-testing after deployment, and a defined escalation path when a clinician notices something a dashboard missed. The difference is not extra paperwork for its own sake. It is the only way to catch the gap between what a tool promises and what it delivers for the patient actually in the room.

Our partner HaiPhai’s work on where AI can help in regulatory affairs makes a related point for life sciences teams more broadly: governed automation works best when human oversight is deliberately designed into the workflow rather than assumed to be there by default. The same logic applies directly to clinical AI procurement.

Pro Tip: Before signing off on any AI tool, ask the vendor for subgroup-level sensitivity and specificity, not just an overall accuracy figure. A supplier who cannot produce this has not tested for the harm you are trying to avoid.

Mitigation strategies mapped to lifecycle stage

Fixing bias is easier and cheaper the earlier in the lifecycle you intervene, but every stage offers a genuine lever.

At the design stage, inclusive data design means deliberately sourcing or oversampling under-represented cohorts rather than hoping a large dataset will naturally balance out. For data involving Aboriginal and Torres Strait Islander communities, that means engaging Indigenous data governance principles from the outset, since the 2025 National Review on safe and responsible AI in health care specifically recommends stronger Indigenous data sovereignty protections as part of bias mitigation.

At the dataset stage, reweighting under-represented subgroups during training, synthetic data augmentation for thin cohorts and deliberate stratified sampling are the standard toolkit. None of these substitute for genuinely diverse source data, but they reduce the damage when perfect data is not available.

At the modelling stage, adversarial debiasing techniques train a model to perform a clinical task while simultaneously penalising it for encoding protected attributes in its internal representations. Explainability-aware pruning is a newer and more targeted approach: recent UNSW research on transformer-based medical image analysis shows that identifying and removing the specific internal nodes responsible for discriminatory behaviour can reduce bias while preserving core classification performance, though the authors note these methods need further clinical validation before routine deployment.

At the post-processing stage, subgroup-specific threshold adjustment and calibration recalibrate a model’s decision boundary separately for each cohort, correcting for systematic over- or under-confidence without retraining the entire model. This is often the fastest fix available once a disparity is detected in a deployed tool.

At the deployment and monitoring stage, the controls that matter most are operational rather than mathematical:

  • Configurable fairness thresholds let a health service set its own tolerance for subgroup performance gaps, rather than accepting a vendor’s default.
  • Scheduled monitoring dashboards track subgroup performance over time, not just at initial validation.
  • Clinician override must remain genuinely available and genuinely used, since a model is decision support, not a decision.
  • Documented escalation pathways ensure a flagged disparity reaches someone with authority to pause or adjust the tool.

The AHRC technical paper is blunt about the limits of technical fixes alone: effective mitigation is socio-technical, meaning organisations need multidisciplinary stakeholder engagement and lived-experience representation alongside the engineering work. A reweighted model built without input from the clinicians and communities it affects is still likely to miss problems that only surface in practice.

Pro Tip: Treat a fairness threshold the same way you treat a clinical alert threshold: document who set it, why, and when it was last reviewed.

Governance, regulation and professional responsibilities

Using a clinical AI tool does not transfer clinical accountability away from the practitioner. AHPRA and National Board guidance is clear that practitioners need to understand how an AI tool was trained and tested, and must inform patients when AI contributes to their care. TGA approval of a device is not a substitute for that ongoing professional judgement, a point the Safety and Quality Commission’s pragmatic AI guidance makes explicitly: regulatory clearance does not remove clinician responsibility for evidence review, understanding limitations and ongoing monitoring.

At the system level, AI technical standard’s Statement 6 sets out the obligations health services and developers must meet:

  • Manage bias across the full lifecycle, not only at initial validation, including documented review at defined intervals.
  • Report disaggregated performance metrics for any system affecting diagnosis, triage or resource allocation.
  • Engage stakeholders, including clinicians and, where relevant, community representatives, in reviewing fairness outcomes.
  • Maintain audit documentation that records what was tested, what was found and what action followed.

The 2025 national review on safe and responsible AI in health care found bias a consistent theme across public consultation, alongside data access, transparency and human oversight, and recommended both stronger pre-market data governance and mandatory post-market surveillance. For procurement teams, that translates into a practical expectation: do not accept a vendor’s validation study as the end of the conversation, and build monitoring and reporting obligations into the contract itself.

Privacy and consent sit alongside bias as part of the same governance picture. Patients have a reasonable expectation to know when AI is shaping their care, and health services need documented consent processes that reflect this, not a generic privacy notice.

Tools, frameworks and a practical checklist you can adopt this week

Most of the mitigation discussed above becomes workable once it is turned into a repeatable checklist rather than a one-off project.

  1. Request disaggregated validation data for any AI tool already in use, broken down by age, sex and ethnicity where data permits.
  2. Identify thin subgroups in your own patient population where sample sizes are too small for the vendor’s reported metrics to be reliable for your context.
  3. Set a monitoring cadence, for example quarterly, to re-check subgroup performance rather than relying on the original validation study indefinitely.
  4. Define an escalation pathway so a clinician who notices a disparity knows exactly who to tell and what happens next.
  5. Document consent language confirming patients are informed when AI contributes to a clinical decision affecting them.
  6. Add fairness questions to procurement templates, including a requirement for subgroup-level results before any contract is signed.

The Future‑AI international consensus guideline frames fairness as fundamentally socioethical rather than purely technical, which is a useful reminder when building this checklist: a governance committee with only data scientists at the table will miss things a committee with clinicians, patients and ethicists will not.

For teams building out procurement standards, our guide to Australian healthcare data governance in five pillars walks through how to structure these requirements into a repeatable procurement process, and our piece on consent management covers the practical steps for aligning consent language with OAIC expectations.

Example: how an algorithmic patient-matching platform can operationalise fairness controls

We built Meddle’s matching system around a principle we think every clinical algorithm should follow: a match should come with a rationale a clinician can actually inspect, not a black-box score. Every recommendation our algorithm generates is paired with a readable explanation of why that practitioner was suggested, which supports clinical oversight rather than replacing it.

We also keep matching thresholds configurable and monitor outcomes continuously, rather than treating a single launch-time validation as sufficient. Our guide to how AI patient matching works and our piece on algorithmic patient triage, where we discuss our approach to monitoring and explainability as ongoing obligations rather than one-off features.

A practitioner’s view on getting bias testing off the ground

The biggest barrier to bias testing is rarely technical. It is cultural: teams assume the vendor already checked this, or worry that raising the question will slow down a rollout everyone is keen to finish. Smaller health services also genuinely lack the data science capacity to run a full audit alone.

Start smaller than you think you need to. A pilot that disaggregates results for just two or three subgroups, reviewed by a standing governance committee rather than a one-off meeting, teaches you more than waiting for the perfect audit framework. The one thing to do this week: pull the validation report for whichever AI tool you already use most, and check whether it reports a single accuracy figure or a breakdown by patient group. If it is one number, that is your first finding.

— Taylor

FAQ

What is algorithmic bias in healthcare?

Algorithmic bias in healthcare is when an AI system produces systematically less accurate or less favourable outcomes for particular patient groups, even when its overall reported accuracy looks strong. It typically arises from unrepresentative training data, biased labels, proxy variables or feedback loops created after deployment.

How do you detect bias in a medical algorithm?

Detection relies on disaggregating performance metrics such as sensitivity, specificity and calibration by subgroup, including age, sex and ethnicity, rather than relying on one aggregate figure. Counterfactual testing, where a single demographic attribute is changed to see if the output shifts unfairly, and ongoing post-market monitoring, add further layers of detection, as recommended in NSW ACI guidance.

What should a fairness audit for clinical AI include?

A fairness audit should include subgroup-level sensitivity, specificity and calibration, documented data provenance, counterfactual and edge-case stress tests, and a defined escalation pathway for findings. The AI technical standard’s Statement 6 requires this kind of disaggregated, lifecycle-wide approach rather than a single pre-launch check.

Who is responsible when a biased algorithm harms a patient?

The treating clinician and health service remain professionally and legally accountable for decisions made with AI support, regardless of regulatory approval of the underlying tool. AHPRA and National Board guidance confirms that practitioners must understand a tool’s limitations and exercise independent clinical judgement rather than deferring to its output.

Can bias in medical AI be fixed after deployment?

Yes, through post-processing techniques such as subgroup-specific threshold recalibration, ongoing monitoring and, where needed, retraining with more representative data. Emerging methods like explainability-aware pruning, studied in recent UNSW research, show promise for reducing bias in imaging models without major performance loss, though further clinical validation is still needed.

Sources